Literature DB >> 21071521

Tissue distribution and elimination of [14C]apixaban in rats.

Lifei Wang1, Kan He, Brad Maxwell, Scott J Grossman, Larry M Tremaine, W Griffith Humphreys, Donglu Zhang.   

Abstract

Apixaban, a potent and highly selective factor Xa inhibitor, is currently under development for treatment of arterial and venous thrombotic diseases. The distribution, metabolism, and elimination of [(14)C]apixaban were investigated in male, female, pregnant, and lactating rats after single oral doses. Tissue distribution of radioactivity in rats was measured using quantitative whole-body autoradiography. After a single oral administration, radioactivity distributed quickly in rats with C(max) at 1 h for most tissues. The elimination t(1/2) of radioactivity in blood was 1.7 to 4.2 h. The blood area under the plasma concentration-time curve of radioactivity was similar between male and female rats and was slightly higher in pregnant rats and lower in lactating rats. The radioactivity concentration in tissues involved in elimination was greater than that in blood with the highest concentration in the gastrointestinal tract, liver, and urinary bladder/contents and lowest level in brains. In pregnant rats, the whole-body autoradiogram showed that low levels of radioactivity were present in fetal blood, liver, and kidney and were much lower than the radioactivity in the respective maternal organs. The fecal route was the major pathway (74% of dose), and the urinary route was the minor pathway (14%) for apixaban elimination. After single oral doses of [(14)C]apixaban to lactating rats, apixaban exhibited extensive lacteal excretion with apixaban as the major component. In summary, tissue distribution of apixaban in rats was extensive but with limited transfer to fetal and brain tissues and extensive secretion into rat milk with the parent drug as the major component. Milk excretion could account for 10% of apixaban dose, which was comparable to urinary elimination in rats. Tissue distribution and drug excretion of apixaban are consistent with those for a moderately permeable drug that is a substrate for P-glycoprotein and breast cancer resistance protein efflux transporters.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21071521     DOI: 10.1124/dmd.110.036442

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  23 in total

Review 1.  Structure-function relationships of factor Xa inhibitors: implications for the practicing clinician.

Authors:  Benjamin A Steinberg; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

Review 2.  Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review.

Authors:  Boris Arbit; Jonathan C Hsu
Journal:  Clin Cardiol       Date:  2015-07-14       Impact factor: 2.882

Review 3.  Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic Modalities.

Authors:  Donglu Zhang; Cornelis E C A Hop; Gabriela Patilea-Vrana; Gautham Gampa; Herana Kamal Seneviratne; Jashvant D Unadkat; Jane R Kenny; Karthik Nagapudi; Li Di; Lian Zhou; Mark Zak; Matthew R Wright; Namandjé N Bumpus; Richard Zang; Xingrong Liu; Yurong Lai; S Cyrus Khojasteh
Journal:  Drug Metab Dispos       Date:  2019-07-02       Impact factor: 3.922

4.  Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.

Authors:  Charles E Frost; Wonkyung Byon; Yan Song; Jessie Wang; Alan E Schuster; Rebecca A Boyd; Donglu Zhang; Zhigang Yu; Clapton Dias; Andrew Shenker; Frank LaCreta
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

5.  Metabolic disposition of the anti-cancer agent [(14)C]laromustine in male rats.

Authors:  Ala F Nassar; Adam Wisnewski; Ivan King
Journal:  Xenobiotica       Date:  2015-03-23       Impact factor: 1.908

Review 6.  Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.

Authors:  C Stöllberger; J Finsterer
Journal:  Herz       Date:  2015-01-25       Impact factor: 1.443

7.  Direct Carbon Isotope Exchange through Decarboxylative Carboxylation.

Authors:  Cian Kingston; Michael A Wallace; Alban J Allentoff; Justine N deGruyter; Jason S Chen; Sharon X Gong; Samuel Bonacorsi; Phil S Baran
Journal:  J Am Chem Soc       Date:  2019-01-03       Impact factor: 15.419

Review 8.  Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.

Authors:  Jochen Graff; Sebastian Harder
Journal:  Clin Pharmacokinet       Date:  2013-04       Impact factor: 6.447

Review 9.  Novel oral anticoagulants: clinical pharmacology, indications and practical considerations.

Authors:  Sebastian Harder; Jochen Graff
Journal:  Eur J Clin Pharmacol       Date:  2013-04-26       Impact factor: 2.953

10.  Direct oral anticoagulant safety during breastfeeding: a narrative review.

Authors:  Maryam Daei; Hossein Khalili; Zinat Heidari
Journal:  Eur J Clin Pharmacol       Date:  2021-05-08       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.